3 completed, 1 terminated. 2 Phase 4, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Alemtuzumab GZ402673: new trials by email Literature Review of Alemtuzumab GZ402673 trials Research Report on Alemtuzumab GZ402673
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis | Phase 3 | Terminated | Genzyme, a Sanofi Company | 16 | 2017-10-23 | 2026-08-04 |
| A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis Acyclovir, Methylprednisolone, alemtuzumab GZ402673 - Progressive Multiple Sclerosis | Phase 1 | Completed | Genzyme, a Sanofi Company | 24 | 2015-12-06 | 2021-03-10 |
| Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 alemtuzumab GZ402673 - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Genzyme, a Sanofi Company | 1062 | 2015-01-07 | 2022-03-28 |
| Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Alemtuzumab GZ402673, cetirizine, ranitidine - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Genzyme, a Sanofi Company | 58 | 2014-10-01 | 2016-06-09 |
Multiple Sclerosis, Relapsing-Remitting (2) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1)
Spain (3) · Belgium (2) · France (2) · Italy (2) · Netherlands (2) · Poland (2) · Russia (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1)
PMID 31654272, PMID 31762387, PMID 32583052, PMID 32710396, PMID 33476880, PMID 34378446, PMID 34882037, PMID 37745914, PMID 39513023, PMID 39935588
2014 (1), 2015 (1), 2016 (1)